Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Apolipoprotein E genotype and statins affect CRP levels through independent and different mechanisms: AGES-Reykjavik Study.

Eiriksdottir G, Aspelund T, Bjarnadottir K, Olafsdottir E, Gudnason V, Launer LJ, Harris TB.

Atherosclerosis. 2006 May;186(1):222-4. Epub 2006 Jan 30.

PMID:
16445917
2.

Use of genotype frequencies in medicated groups to investigate prescribing practice: APOE and statins as a proof of principle.

Davies NM, Windmeijer F, Martin RM, Abdollahi MR, Smith GD, Lawlor DA, Ebrahim S, Day IN.

Clin Chem. 2011 Mar;57(3):502-10. doi: 10.1373/clinchem.2010.156356. Epub 2011 Jan 12.

3.

Apolipoprotein E genotype is related to plasma levels of C-reactive protein and lipids and to longevity in nonagenarians.

Rontu R, Ojala P, Hervonen A, Goebeler S, Karhunen PJ, Nikkilä M, Kunnas T, Jylhä M, Eklund C, Hurme M, Lehtimäki T.

Clin Endocrinol (Oxf). 2006 Mar;64(3):265-70.

PMID:
16487435
4.

The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients.

Vaisi-Raygani A, Rahimi Z, Nomani H, Tavilani H, Pourmotabbed T.

Clin Biochem. 2007 Oct;40(15):1150-6. Epub 2007 Jul 6.

PMID:
17689519
6.

Apolipoprotein E epsilon-4 polymorphism is associated with younger age at referral to a lipidology clinic and a poorer response to lipid-lowering therapy.

Baptista R, Rebelo M, Decq-Mota J, Dias P, Monteiro P, Providência LA, Silva JM.

Lipids Health Dis. 2011 Mar 30;10:48. doi: 10.1186/1476-511X-10-48.

7.

Interactive effects of C-reactive protein levels on the association between APOE variants and triglyceride levels in a Taiwanese population.

Wu S, Hsu LA, Teng MS, Lin JF, Chou HH, Lee MC, Wu YM, Su CW, Ko YL.

Lipids Health Dis. 2016 May 13;15:94. doi: 10.1186/s12944-016-0262-z.

8.

ApoE plasma levels and risk of cardiovascular mortality in old age.

Mooijaart SP, Berbée JF, van Heemst D, Havekes LM, de Craen AJ, Slagboom PE, Rensen PC, Westendorp RG.

PLoS Med. 2006 Jun;3(6):e176. Epub 2006 May 9.

9.

Presence of apolipoprotein E epsilon4 allele predisposes to early onset of primary Sjogren's syndrome.

Pertovaara M, Lehtimäki T, Rontu R, Antonen J, Pasternack A, Hurme M.

Rheumatology (Oxford). 2004 Dec;43(12):1484-7. Epub 2004 Aug 24.

PMID:
15328426
10.

Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease.

Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN.

Am J Pathol. 1996 Jun;148(6):2083-95.

11.

Risk of Alzheimer disease with the epsilon4 allele for apolipoprotein E in a population-based study of men aged 62-73 years.

Breitner JC, Jarvik GP, Plassman BL, Saunders AM, Welsh KA.

Alzheimer Dis Assoc Disord. 1998 Mar;12(1):40-4.

PMID:
9539409
12.

Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus.

Tavintharan S, Lim SC, Chan YH, Sum CF.

Diabetes Obes Metab. 2007 Jan;9(1):81-6.

PMID:
17199722
13.

Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein.

Chasman DI, Kozlowski P, Zee RY, Kwiatkowski DJ, Ridker PM.

Genes Immun. 2006 Apr;7(3):211-9.

PMID:
16511556
14.

Apolipoprotein E polymorphism in 385 patients on renal replacement therapy in Sweden.

Roussos L, Ekström U, Ehle PN, Oqvist B, Floren CH.

Scand J Urol Nephrol. 2004;38(6):504-10.

PMID:
15841787
15.

Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran.

Raygani AV, Zahrai M, Raygani AV, Doosti M, Javadi E, Rezaei M, Pourmotabbed T.

Neurosci Lett. 2005 Feb 25;375(1):1-6. Epub 2004 Nov 26.

PMID:
15664112
16.

Effects of ezetimibe on lipids and lipoproteins in patients with hypercholesterolemia and different apolipoprotein E genotypes.

Mark L, Dani G, Fazekas O, Szüle O, Kovacs H, Katona A.

Curr Med Res Opin. 2007 Jul;23(7):1541-8.

PMID:
17559752
17.

Apolipoprotein E epsilon4 allele and familial aggregation of Alzheimer disease.

Martinez M, Campion D, Brice A, Hannequin D, Dubois B, Didierjean O, Michon A, Thomas-Anterion C, Puel M, Frebourg T, Agid Y, Clerget-Darpoux F.

Arch Neurol. 1998 Jun;55(6):810-6.

PMID:
9626772
18.

Association of APOE epsilon2/epsilon3/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age.

Heijmans BT, Slagboom PE, Gussekloo J, Droog S, Lagaay AM, Kluft C, Knook DL, Westendorp RG.

Am J Med Genet. 2002 Jan 22;107(3):201-8.

PMID:
11807900
19.

Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.

Straczek C, Tafflet M, Barberger-Gateau P, Bertrand M, Dupuy AM, Ducimetière P, Empana JP.

Atherosclerosis. 2011 Feb;214(2):426-31. doi: 10.1016/j.atherosclerosis.2010.10.040. Epub 2010 Nov 3.

PMID:
21129746
20.

Apolipoprotein E gene and early age-related maculopathy: the Atherosclerosis Risk in Communities Study.

Wong TY, Shankar A, Klein R, Bray MS, Couper DJ, Klein BE, Sharrett AR, Folsom AR.

Ophthalmology. 2006 Feb;113(2):255-9. Epub 2006 Jan 10.

PMID:
16406547

Supplemental Content

Support Center